A California-based firm is investing from a new fund that closed in early 2016. The firm generally invests in Series A equity rounds, and typically commits a total of $1-4 million over the course of an investment. The firm invests 90% of its capital in the USA, Japan and Israel, with the remaining 10% open to global opportunities.
The firm invests in advanced therapeutics, healthcare IT, novel devices and diagnostics, and second generation tools and technologies in the biotech R&D/laboratory innovation field. Technologies of interest to the firm include 3D tissue scaffolds, organs-on-a-chip, second generation diagnostics, and single cell tracking. The firm is open to any indication area, and has a particular interest in diseases that afflict the elderly including Alzheimer’s disease and cancer. The firm prefers to invest in technologies at an early stage of development.
The firm is interested in working with high quality management teams.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org